Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course I see that. It's called front running. I've been around a long time.
LOL. It's true I have been.
Excuse me! What are you talking about?
I've been in $SYN for a while.
I try to be out before him. No I don't short. You always take a chance when you follow him.
$SYN . I don't like the fact that $SYN was at 2.82 when $heff posts that he sold at 2.92. He knows it's going to drop more when he posts he sold. Screws the people that follow his trades. That's fucked up!
$heff sold.
New Economy & Beginner Portfolio Economy..This market is really ugly here. Been difficult to trade while on vacation so I have basically scaled back all of my positions to starter positions here and made adjustments to my portfolio. I will be back in full swing on Thursday. I am going to trade fewer positions moving forward and they will be near-term catalysts. Need to adjust to this market as changes are being made to preserve capital. Nothing news here. I have always done this to my portfolio in a changing environment. You don't complain about the situation but make changes to it.
Alert..sold SYN at $2.92 in New Economy Portfolio from $2.80 entry on 3/13. I may reenter closer to the catalyst date.
$IDRA Mar 24, 2014 09:34 AM Idera Pharma's (IDRA) IMO-8400 Expected to Fail - Summer Street
http://bit.ly/1oUcFA9
$CMXI .62 up 6.9%
$CMXI .62 up 6.9%
CT I hope so. They need to come out with one that uses no interferon or ribavirin. I used both of them with Victrellis and it almost killed me, had to stop treatment.
Gilead's breakthrough hepatitis C drug is too expensive, medical experts say
By Matthew Perrone
Associated Press
POSTED: 03/11/2014 09:38:21 AM PDT14 COMMENTS| UPDATED: 6 DAYS AGO
WASHINGTON -- An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences.
A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" treatment, considering its cost compared with older drugs for the blood-borne virus.
http://bit.ly/1kgBzb3
$IDRA also from $heff's board.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=98772070&txt2find=idra
PGNX????
"A few weeks ago, according to blog TheHill, Manchin and Senator David Vitter (R-Louisiana) began looking into charges of undue influence by the pharmaceutical industry after complaints began surfacing that industry lobbyists contributed more than $10,000 to obtain meetings with the FDA to discuss Zohydro."
Sort of like the kettle calling the pot black. This is the same thing PACs do with the politicians but the PACs spend millions rather than thousands.
$heff I never thought of it that. I should have. Thanks for the insight.
t2m definitely agree with you on this.
$ETRM needs to get past $2.66 then it can run past $3.00
Strange how different firms have their own rules.
Who do you trade with? On schwab it's not eligible for trading after hours.
$heff just exited @ $2.90
$SYN same here but I'm looking.
$SYN $heff where did you find that news? I must have missed it.
$CERS $7.51
Catalysts
The company is now attempting to receive approval for the product in the United States. Cerus has already completed Phase III trials for the Intercept System for the platelet and plasma indications. On December 4, 2013, the company submitted a Pre-market Approval (PMA) application to the FDA for the plasma indication. Using the FDA's 90-day guideline for review, Cerus should expect to hear about approval by the end of February or very early March for that indication. The company also stated that it is planning to submit the last module of the PMA for platelets by March 2014. Using the same timeline, that would put potential partial approval of the product by May 2014.
Since the company has extensive data from the European Union, the FDA has allowed the company to submit without undergoing more trials. Approval for this product in the United States would increase sales and better position the company to further its trials for the use on red blood cells. Cerus expects both products to be approved and marketed by the second half of 2014. The company seems confident in receiving approval because they just announced additions to a North American sales team. If all things go as planned, 2014 could be an inflection point for the company.
http://bit.ly/1mo01YF
I know that feeling all too well.
$EXAS got in this morning @ $12.62 on the pullback.
Trade resumption @ 5:25
T2 now.
$CHTP The FDA has approved Chelsea Therapeutics' (CHTP) Northera for the treatment of neurogenic orthostatic hypotension (NOH), a rare disease which causes a debilitating drop in blood pressure upon standing.
No announcement yet from Chelsea but here's a snippet from the FDA announcement:
The FDA is approving Northera under the accelerated approval program, which allows for approval of a drug to treat a serious disease based on clinical data showing that the drug has an effect on an intermediate clinical measure (in this case, short-term relief of dizziness) that is reasonably likely to predict the outcome of ultimate interest (relief of dizziness during chronic treatment). This program provides patient access to promising drugs while the company conducts post-approval clinical trials to verify the drug's clinical benefit, which for this approval is a long-term effect on patient symptoms in NOH, a chronic disease.
Northera has a boxed warning to alert health care professionals and patients about the risk of increased blood pressure while lying down (supine hypertension), a common problem that affects people with primary autonomic failure and can cause stroke. It is essential that patients be reminded that they must sleep with their head and upper body elevated. Supine blood pressure should be monitored prior to and during treatment and more frequently when increasing doses.
The most common adverse events reported by clinical trial participants taking Northera were headache, dizziness, nausea, high blood pressure (hypertension) and fatigue.
The effectiveness of Northera was shown through two-weeks in two clinical trials in people with NOH. People taking Northera reported a decrease in dizziness, lightheadedness, feeling faint, or feeling as if they might black out compared to those taking an inactive pill (placebo). Durability of the improvement in patient symptoms beyond two weeks has not been demonstrated.
http://bit.ly/1faAaTz
Congrats longs.
approved!
Down a shot and have a hit. That should help. I'm doing the latter. Fresh blueberry.
Looking for you to make gains not losses.
Could be a bitch getting out of all that with any speed if needed.
Are you all stock or have options also?